S&P/ASX All Ords (ASX: XAO) shares fell 3.2% in December in an unusually weak final month of the year.
Meantime, some brokers changed their ratings on various ASX stocks before heading off on holidays.
Here are six ASX All Ords shares that market analysts on the CommSec trading platform upgraded to a consensus 'strong buy' rating last month.
6 ASX All Ords shares lifted to 'strong buy' status
Telstra Group Ltd (ASX: TLS)
Analysts upgraded their consensus rating on Telstra shares to a strong buy on 23 December.
The Telstra share price is $4.02, up 0.25%.
Goldman Sachs has a buy rating on Telstra with a 12-month share price target of $4.50. This implies a potential 12% upside for investors in 2025.
In a new note, analysts Kate Hannan and Annabel Li discussed the recent sale of Foxtel to global sports streaming platform, DAZN for $3.4 billion.
Under the deal, Telstra will also sell its minority stake in Foxtel. It will receive $128 million in cash to repay a loan, as well as an approximate 3% shareholding in DAZN.
Hannan and Li explained their buy rating on Telstra shares:
We believe the low risk earnings (and dividend) growth that Telstra is delivering across FY22-25, underpinned through its mobile business, is attractive.
We also believe that Telstra has a meaningful medium term opportunity to crystallise value through commencing the process to monetize its InfraCo Fixed assets — which we estimate could be worth between A$22-33bn.
The ASX All All Ords telecommunications share is up 1.01% over the past 12 months.
Liberty Group (ASX: LFG)
Analysts upgraded their consensus rating on Liberty Group shares to a strong buy on 13 December.
The Liberty share price is currently steady at $3.32.
The ASX All Ords financial share is down 19.2% over the past 12 months.
Integral Diagnostics Ltd (ASX: IDX)
Analysts upgraded their consensus rating on Integral Diagnostics shares on 27 December.
The Integral Diagnostics share price is trading at $2.91 on Thursday.
Bell Potter is among the analysts with a buy rating on this ASX All Ords healthcare stock.
The broker has a 12-month price target of $3.87, implying a potential upside of 33% for the medical imaging company in 2025.
The ASX All Ords healthcare share is up 50.7% over the past 12 months.
Helloworld Travel Ltd (ASX: HLO)
Analysts on CommSec upgraded their consensus rating on Helloworld shares on 13 December.
The Helloworld Travel share price is currently $1.97, up 0.87%.
The ASX All All Ords travel share is down 19.2% over the past 12 months.
Paradigm Biopharmaceuticals Ltd (ASX: PAR)
Analysts upgraded their consensus rating on Paradigm shares to a strong buy on 13 December.
The Paradigm Biopharmaceuticals share price is 39 cents, up 2.67% on Thursday.
Bell Potter has a speculative buy rating on the biotech, which is focused on repurposing Pentosan Polysulfate Sodium (PPS) for the treatment of knee osteoarthritis.
The broker is encouraged by trial data and the possibility of phase 3 studies starting in the new year. Its 12-month price target is 80 cents per share, suggesting a potential upside of 105% in 2025.
The ASX All Ords healthcare share is down 14.4% over the past 12 months.
Cobram Estate Olives Ltd (ASX: CBO)
Analysts upgraded their consensus rating on Cobram shares to a strong buy on 16 December.
The Cobram Estate share price is $2.13, down 0.93% on Thursday.
This ASX All Ords consumer staples share is up 21.7% over the past 12 months.
